An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction

Trial Profile

An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 05 Jun 2018 Results (n=1229) assessing whether patients could still benifit from continuing apatinib treatment after failure of apatinib as third line or beyond therapy presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results (n=1468, data cut off dec 21, 2017) assessing safety, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results (n=1468, data cut off dec 21, 2017), were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top